Annual EBIT
$86.81 M
-$15.03 M-14.75%
31 December 2023
Summary:
Catalyst Pharmaceuticals annual earnings before interest & taxes is currently $86.81 million, with the most recent change of -$15.03 million (-14.75%) on 31 December 2023. During the last 3 years, it has risen by +$45.51 million (+110.18%). CPRX annual EBIT is now -14.75% below its all-time high of $119.69 million.CPRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
$50.91 M
-$3.34 M-6.15%
30 September 2024
Summary:
Catalyst Pharmaceuticals quarterly earnings before interest & taxes is currently $50.91 million, with the most recent change of -$3.34 million (-6.15%) on 30 September 2024. Over the past year, it has increased by +$88.10 million (+236.90%). CPRX quarterly EBIT is now -6.15% below its all-time high of $54.25 million, reached on 30 June 2024.CPRX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
$173.97 M
+$88.10 M+102.59%
30 September 2024
Summary:
Catalyst Pharmaceuticals TTM earnings before interest & taxes is currently $173.97 million, with the most recent change of +$88.10 million (+102.59%) on 30 September 2024. Over the past year, it has increased by +$98.05 million (+129.15%). CPRX TTM EBIT is now at all-time high.CPRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CPRX EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.8% | +236.9% | +129.2% |
| 3 y3 years | +110.2% | +263.5% | +260.5% |
| 5 y5 years | +346.0% | +267.7% | +1838.8% |
CPRX EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -14.8% | +110.2% | -6.2% | +236.9% | at high | +260.5% |
| 5 y | 5 years | -14.8% | +346.0% | -6.2% | +236.9% | at high | +1838.8% |
| alltime | all time | -14.8% | +346.0% | -6.2% | +236.9% | at high | +592.9% |
Catalyst Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $50.91 M(-6.2%) | $173.97 M(+102.6%) |
| June 2024 | - | $54.25 M(+100.0%) | $85.88 M(+9.6%) |
| Mar 2024 | - | $27.13 M(-34.9%) | $78.33 M(-9.8%) |
| Dec 2023 | $86.81 M(-14.8%) | $41.69 M(-212.1%) | $86.81 M(+14.3%) |
| Sept 2023 | - | -$37.19 M(-179.6%) | $75.92 M(-45.1%) |
| June 2023 | - | $46.70 M(+31.1%) | $138.21 M(+15.1%) |
| Mar 2023 | - | $35.61 M(+15.6%) | $120.08 M(+17.9%) |
| Dec 2022 | $101.84 M(+94.4%) | $30.80 M(+22.7%) | $101.84 M(+21.6%) |
| Sept 2022 | - | $25.10 M(-12.1%) | $83.78 M(+15.3%) |
| June 2022 | - | $28.57 M(+64.5%) | $72.68 M(+21.2%) |
| Mar 2022 | - | $17.37 M(+36.3%) | $59.95 M(+14.4%) |
| Dec 2021 | $52.38 M(+26.8%) | $12.74 M(-9.0%) | $52.38 M(+8.5%) |
| Sept 2021 | - | $14.00 M(-11.6%) | $48.26 M(+5.0%) |
| June 2021 | - | $15.84 M(+61.6%) | $45.96 M(+13.8%) |
| Mar 2021 | - | $9.80 M(+13.7%) | $40.41 M(-2.2%) |
| Dec 2020 | $41.30 M(+29.8%) | $8.62 M(-26.4%) | $41.30 M(+1.5%) |
| Sept 2020 | - | $11.70 M(+13.8%) | $40.69 M(-5.0%) |
| June 2020 | - | $10.28 M(-3.9%) | $42.83 M(-1.6%) |
| Mar 2020 | - | $10.70 M(+33.6%) | $43.51 M(+36.7%) |
| Dec 2019 | $31.82 M(-190.2%) | $8.01 M(-42.2%) | $31.82 M(+254.6%) |
| Sept 2019 | - | $13.85 M(+26.3%) | $8.97 M(-168.7%) |
| June 2019 | - | $10.96 M(-1209.5%) | -$13.05 M(-57.0%) |
| Mar 2019 | - | -$987.80 K(-93.3%) | -$30.35 M(-14.0%) |
| Dec 2018 | -$35.30 M(+89.0%) | -$14.84 M(+81.4%) | -$35.30 M(+35.9%) |
| Sept 2018 | - | -$8.18 M(+29.1%) | -$25.96 M(+17.5%) |
| June 2018 | - | -$6.34 M(+6.8%) | -$22.09 M(+10.8%) |
| Mar 2018 | - | -$5.93 M(+7.6%) | -$19.93 M(+6.7%) |
| Dec 2017 | -$18.68 M(-3.1%) | -$5.51 M(+28.0%) | -$18.68 M(+6.9%) |
| Sept 2017 | - | -$4.31 M(+3.0%) | -$17.48 M(+2.3%) |
| June 2017 | - | -$4.18 M(-10.7%) | -$17.09 M(-3.6%) |
| Mar 2017 | - | -$4.68 M(+8.5%) | -$17.72 M(-8.1%) |
| Dec 2016 | -$19.28 M(-5.5%) | -$4.31 M(+10.2%) | -$19.28 M(-8.9%) |
| Sept 2016 | - | -$3.91 M(-18.7%) | -$21.16 M(-5.0%) |
| June 2016 | - | -$4.81 M(-22.8%) | -$22.26 M(-0.4%) |
| Mar 2016 | - | -$6.24 M(+0.7%) | -$22.34 M(+9.5%) |
| Dec 2015 | -$20.40 M(+39.8%) | -$6.19 M(+23.4%) | -$20.40 M(+12.1%) |
| Sept 2015 | - | -$5.02 M(+2.5%) | -$18.19 M(+5.3%) |
| June 2015 | - | -$4.90 M(+14.1%) | -$17.28 M(+12.4%) |
| Mar 2015 | - | -$4.29 M(+7.7%) | -$15.38 M(+5.4%) |
| Dec 2014 | -$14.59 M | -$3.98 M(-3.0%) | -$14.59 M(+9.6%) |
| Sept 2014 | - | -$4.11 M(+37.4%) | -$13.31 M(+6.9%) |
| June 2014 | - | -$2.99 M(-14.8%) | -$12.45 M(+2.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | -$3.51 M(+29.6%) | -$12.11 M(+17.5%) |
| Dec 2013 | -$10.31 M(+97.5%) | -$2.71 M(-16.6%) | -$10.31 M(+13.2%) |
| Sept 2013 | - | -$3.25 M(+22.3%) | -$9.11 M(+27.4%) |
| June 2013 | - | -$2.65 M(+55.6%) | -$7.15 M(+28.5%) |
| Mar 2013 | - | -$1.71 M(+13.3%) | -$5.56 M(+6.5%) |
| Dec 2012 | -$5.22 M(-14.2%) | -$1.51 M(+17.3%) | -$5.22 M(-9.2%) |
| Sept 2012 | - | -$1.28 M(+20.3%) | -$5.75 M(+2.7%) |
| June 2012 | - | -$1.07 M(-21.8%) | -$5.60 M(-5.6%) |
| Mar 2012 | - | -$1.36 M(-32.9%) | -$5.93 M(-2.5%) |
| Dec 2011 | -$6.08 M(+51.1%) | -$2.03 M(+79.9%) | -$6.08 M(+27.2%) |
| Sept 2011 | - | -$1.13 M(-19.1%) | -$4.78 M(+4.9%) |
| June 2011 | - | -$1.40 M(-8.0%) | -$4.56 M(+1.4%) |
| Mar 2011 | - | -$1.52 M(+107.5%) | -$4.49 M(+11.6%) |
| Dec 2010 | -$4.02 M(-44.7%) | -$732.20 K(-19.4%) | -$4.02 M(-9.8%) |
| Sept 2010 | - | -$908.50 K(-31.9%) | -$4.46 M(-7.9%) |
| June 2010 | - | -$1.33 M(+26.9%) | -$4.85 M(-8.3%) |
| Mar 2010 | - | -$1.05 M(-10.2%) | -$5.28 M(-27.4%) |
| Dec 2009 | -$7.28 M(-33.2%) | -$1.17 M(-9.5%) | -$7.28 M(-26.5%) |
| Sept 2009 | - | -$1.29 M(-26.9%) | -$9.90 M(-14.1%) |
| June 2009 | - | -$1.77 M(-41.9%) | -$11.52 M(-5.7%) |
| Mar 2009 | - | -$3.04 M(-19.7%) | -$12.21 M(+12.1%) |
| Dec 2008 | -$10.89 M(+116.7%) | -$3.79 M(+30.1%) | -$10.89 M(+32.1%) |
| Sept 2008 | - | -$2.91 M(+18.3%) | -$8.25 M(+31.3%) |
| June 2008 | - | -$2.46 M(+42.9%) | -$6.28 M(+19.5%) |
| Mar 2008 | - | -$1.72 M(+50.9%) | -$5.25 M(+4.5%) |
| Dec 2007 | -$5.03 M(+73.2%) | -$1.14 M(+20.2%) | -$5.03 M(+5.4%) |
| Sept 2007 | - | -$950.40 K(-33.9%) | -$4.77 M(-7.6%) |
| June 2007 | - | -$1.44 M(-4.0%) | -$5.16 M(+26.5%) |
| Mar 2007 | - | -$1.50 M(+69.1%) | -$4.08 M(+39.9%) |
| Dec 2006 | -$2.90 M(+59.3%) | -$885.20 K(-34.0%) | -$2.92 M(-13.0%) |
| Sept 2006 | - | -$1.34 M(+276.0%) | -$3.35 M(+48.8%) |
| June 2006 | - | -$357.00 K(+7.1%) | -$2.25 M(-11.9%) |
| Mar 2006 | - | -$333.40 K(-74.8%) | -$2.56 M(-11.3%) |
| Dec 2005 | -$1.82 M(+235.6%) | -$1.32 M(+446.4%) | -$2.89 M(+69.9%) |
| Sept 2005 | - | -$241.90 K(-63.4%) | -$1.70 M(+6.7%) |
| June 2005 | - | -$660.80 K(0.0%) | -$1.59 M(+49.3%) |
| Mar 2005 | - | -$660.80 K(+389.5%) | -$1.07 M(+97.4%) |
| Dec 2004 | -$543.00 K(+26.7%) | -$135.00 K(0.0%) | -$540.00 K(+33.3%) |
| Sept 2004 | - | -$135.00 K(0.0%) | -$405.00 K(+50.0%) |
| June 2004 | - | -$135.00 K(0.0%) | -$270.00 K(+100.0%) |
| Mar 2004 | - | -$135.00 K | -$135.00 K |
| Dec 2003 | -$428.60 K(+67.5%) | - | - |
| Dec 2002 | -$255.90 K | - | - |
FAQ
- What is Catalyst Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual EBIT year-on-year change?
- What is Catalyst Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly EBIT year-on-year change?
- What is Catalyst Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals TTM EBIT year-on-year change?
What is Catalyst Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of CPRX is $86.81 M
What is the all time high annual EBIT for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual earnings before interest & taxes is $119.69 M
What is Catalyst Pharmaceuticals annual EBIT year-on-year change?
Over the past year, CPRX annual earnings before interest & taxes has changed by -$15.03 M (-14.75%)
What is Catalyst Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of CPRX is $50.91 M
What is the all time high quarterly EBIT for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly earnings before interest & taxes is $54.25 M
What is Catalyst Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, CPRX quarterly earnings before interest & taxes has changed by +$88.10 M (+236.90%)
What is Catalyst Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of CPRX is $173.97 M
What is the all time high TTM EBIT for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high TTM earnings before interest & taxes is $173.97 M
What is Catalyst Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, CPRX TTM earnings before interest & taxes has changed by +$98.05 M (+129.15%)